Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL2320645 | 0.85 | MAPT (0.31) | DGAT1MAPT | |
| SCHEMBL2315068 | 0.69 | NPC1 (0.32) | DGAT1NPC1MAPT | |
| SCHEMBL2317057 | 0.69 | MAPT (0.35) | DGAT1NPC1MAPT | |
| SCHEMBL2320195 | 0.67 | ALOX15 (0.37) | DGAT1NPC1MAPT | |
| SCHEMBL2315378 | 0.64 | TDP1 (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL23624799 | 0.64 | KMT2A (0.41) | DGAT1NPC1MAPT | |
| SCHEMBL2317262 | 0.63 | BRD4 (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL24541774 | 0.62 | NPC1 (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL16261059 | 0.62 | NPC1 (0.39) | DGAT1NPC1MAPT | |
| SCHEMBL2318529 | 0.62 | FLT3 (0.36) | DGAT1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | DGAT1 2419/4885DHFR 211/4885AKT1 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.